Latest Headlines
-
Medicure Receives US FDA Fast Track Designation For MC-1 For PNPO Deficiency
4/23/2024
Medicure Inc. ("Medicure" or the "Company") a company focused on the development and commercialization of pharmaceuticals and healthcare products for patients and prescribers in the United States market, announced today that through its subsidiary, Medicure International Inc., the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for MC-1, an investigational product for the prevention or treatment of seizures associated with pyridox(am)ine 5'-phosphate oxidase (PNPO) deficiency.
-
FDA Approves Immunotherapy Drug Combo For Non-Muscle Invasive Bladder Cancer After UCLA-Led Research Shows Improved Outcomes For Patients
4/23/2024
The U.S. Food and Drug Administration (FDA) has approved the immunotherapy-boosting drug N-803, which is marketed under the brand name Anktiva, to be used in combination with the immunotherapy Bacillus Calmette-Guerin (BCG) for the treatment of patients with BCG-unresponsive non–muscle-invasive bladder cancer.
-
Takeda, Astellas And Sumitomo Mitsui Banking Announce Master Agreement To Establish Joint Venture Company For Incubation Of Early Drug Discovery Programs
4/22/2024
Takeda Pharmaceutical Company Limited (TSE: 4502/NYSE: TAK, President and CEO; Christophe Weber, "Takeda"), Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas"), and Sumitomo Mitsui Banking Corporation (President & CEO: Akihiro Fukutome, "SMBC") today announced that the three companies signed a master agreement on April 22, 2024, to establish a joint venture company.
-
New Copper-Catalyzed C-H Activation Strategy From Scripps Research
4/19/2024
Inspired by what human liver enzymes can do, Scripps Research chemists have developed a new set of copper-catalyzed organic synthesis reactions for building and modifying pharmaceuticals and other molecules.
-
AI Speeds Up Drug Design For Parkinson’s Ten-Fold
4/17/2024
The researchers, from the University of Cambridge, designed and used an AI-based strategy to identify compounds that block the clumping, or aggregation, of alpha-synuclein, the protein that characterises Parkinson’s.
-
A New Generation Of Antidepressant Drug Precision Treatment Based On Revolutionary AI Technology Is Born
4/17/2024
The9 Limited (Nasdaq: NCTY) ("The9"), an established Internet company, today announced that its investee WM Therapeutics Co., Ltd. (未名脑脑) ("WM Therapeutics") has achieved revolutionary breakthroughs in the proprietarily developed research and development of antidepressant drug precision treatment.
-
Shape-Shifting Cancer Cell Discovery Reveals Potential Skin Cancer Drug Targets
4/17/2024
A new technique allows scientists to see cells in 3D, and determine how different genes affect the shapes they adopt.
-
CureVac And MD Anderson Enter Strategic Collaboration To Develop Novel Cancer Vaccines
4/16/2024
CureVac N.V. a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid ("mRNA"), and The University of Texas MD Anderson Cancer Center today announced a co-development and licensing agreement to develop novel mRNA-based cancer vaccines.
-
Improving Drug Development With A Vast Map Of The Immune System
4/11/2024
The human immune system is a network made up of trillions of cells that are constantly circulating throughout the body.
-
Scripps Research Chemists Devise Easier New Method For Making A Common Type Of Building Block For Drugs
4/11/2024
Ring-shaped chemical structures called saturated heterocycles are found in most FDA-approved drugs but are often difficult to create. Scripps Research chemists have just developed a surprisingly easy method for making many of these sought-after compounds from inexpensive starting chemicals.